TRILYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 420g, sodium chloride 11.2g, potassium chloride 1.48g, sodium bicarbonate 5.72g, flavor 3.22g/pack; per 4 liters of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for TRILYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy.
After fasting for 3–4 hrs, 240mL orally every 10 minutes or 20–30mL/minute by NG tube until rectal discharge is clear or 4 liters consumed. May interrupt if severe GI disturbances occur. Only clear liquids until exam.
<6months: not recommended. ≥6months: No solid food for at least 2 hrs, then 25mL/kg per hour orally or by NG tube until rectal discharge is clear or 4 liters consumed. May interrupt if severe GI disturbances occur. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Pregnancy (Cat.C). Monitor young children (<2yrs) for hypoglycemia or dehydration.
Drugs administered within 1 hour of start of TriLyte may not be absorbed.
Isosmotic bowel cleanser.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation. Children: dehydration, hypokalemia.
TriLyte w. Flavor Packs—4L (disposable bottle w. flavor packs attached)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|